George J. Eiermann

5.0k total citations
30 papers, 1.4k citations indexed

About

George J. Eiermann is a scholar working on Cellular and Molecular Neuroscience, Endocrinology, Diabetes and Metabolism and Oncology. According to data from OpenAlex, George J. Eiermann has authored 30 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Cellular and Molecular Neuroscience, 20 papers in Endocrinology, Diabetes and Metabolism and 17 papers in Oncology. Recurrent topics in George J. Eiermann's work include Diabetes Treatment and Management (20 papers), Neuropeptides and Animal Physiology (20 papers) and Peptidase Inhibition and Analysis (17 papers). George J. Eiermann is often cited by papers focused on Diabetes Treatment and Management (20 papers), Neuropeptides and Animal Physiology (20 papers) and Peptidase Inhibition and Analysis (17 papers). George J. Eiermann collaborates with scholars based in United States, Denmark and Italy. George J. Eiermann's co-authors include Nancy A. Thornberry, Aleksandr Petrov, Ann E. Weber, Joseph K. Wu, Huaibing He, Ranabir SinhaRoy, Gary G. Chicchi, Alessandro Pocai, Barbara Leiting and Giovanna Scapin and has published in prestigious journals such as Diabetes, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

George J. Eiermann

30 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
George J. Eiermann United States 22 660 561 407 375 303 30 1.4k
Hisashi Shinkai Japan 14 436 0.7× 573 1.0× 127 0.3× 112 0.3× 498 1.6× 27 1.6k
Jeffrey A. Robl United States 23 230 0.3× 1.0k 1.8× 128 0.3× 182 0.5× 157 0.5× 61 1.9k
Nobuyuki Negoro Japan 24 445 0.7× 635 1.1× 132 0.3× 79 0.2× 478 1.6× 44 1.5k
T. Saeki Japan 19 238 0.4× 450 0.8× 85 0.2× 108 0.3× 261 0.9× 60 1.0k
Yū Momose Japan 16 492 0.7× 1.0k 1.8× 130 0.3× 99 0.3× 335 1.1× 30 1.7k
Franklin Liu United States 13 357 0.5× 748 1.3× 138 0.3× 264 0.7× 261 0.9× 17 1.4k
Robert J. Ife United Kingdom 23 138 0.2× 865 1.5× 119 0.3× 244 0.7× 432 1.4× 52 1.7k
Paige E. Mahaney United States 15 203 0.3× 487 0.9× 60 0.1× 211 0.6× 434 1.4× 27 1.0k
Ernst U. Frevert United States 16 408 0.6× 1.2k 2.1× 39 0.1× 154 0.4× 521 1.7× 24 1.7k
Ralph Mosley United States 12 163 0.2× 698 1.2× 96 0.2× 54 0.1× 143 0.5× 15 1.2k

Countries citing papers authored by George J. Eiermann

Since Specialization
Citations

This map shows the geographic impact of George J. Eiermann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by George J. Eiermann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites George J. Eiermann more than expected).

Fields of papers citing papers by George J. Eiermann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by George J. Eiermann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by George J. Eiermann. The network helps show where George J. Eiermann may publish in the future.

Co-authorship network of co-authors of George J. Eiermann

This figure shows the co-authorship network connecting the top 25 collaborators of George J. Eiermann. A scholar is included among the top collaborators of George J. Eiermann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with George J. Eiermann. George J. Eiermann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Cox, Jason M., Jeffrey T. Kuethe, Ying‐Duo Gao, et al.. (2016). The discovery of novel 5,6,5- and 5,5,6-tricyclic pyrrolidines as potent and selective DPP-4 inhibitors. Bioorganic & Medicinal Chemistry Letters. 26(11). 2622–2626. 19 indexed citations
3.
Bianchi, Elisabetta, Paul E. Carrington, Paolo Ingallinella, et al.. (2013). A PEGylated analog of the gut hormone oxyntomodulin with long-lasting antihyperglycemic, insulinotropic and anorexigenic activity. Bioorganic & Medicinal Chemistry. 21(22). 7064–7073. 40 indexed citations
4.
5.
Day, Jonathan W., Vasily M. Gelfanov, David L. Smiley, et al.. (2012). Optimization of co‐agonism at GLP‐1 and glucagon receptors to safely maximize weight reduction in DIO‐rodents. Biopolymers. 98(5). 443–450. 111 indexed citations
6.
Li, Xiaoyan, James Herrington, Aleksandr Petrov, et al.. (2012). The Role of Voltage-Gated Potassium Channels Kv2.1 and Kv2.2 in the Regulation of Insulin and Somatostatin Release from Pancreatic Islets. Journal of Pharmacology and Experimental Therapeutics. 344(2). 407–416. 60 indexed citations
7.
Walsh, Shawn P., Changyou Zhou, Jiafang He, et al.. (2011). 3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists. Bioorganic & Medicinal Chemistry Letters. 21(11). 3390–3394. 20 indexed citations
8.
Edmondson, Scott D., Anthony Mastracchio, Jason M. Cox, et al.. (2009). Aminopiperidine-fused imidazoles as dipeptidyl peptidase-IV inhibitors. Bioorganic & Medicinal Chemistry Letters. 19(15). 4097–4101. 33 indexed citations
9.
Mu, James, Aleksandr Petrov, George J. Eiermann, et al.. (2009). Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. European Journal of Pharmacology. 623(1-3). 148–154. 116 indexed citations
10.
Vora, Kalpit A., Gene Porter, Yan Cui, et al.. (2009). Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses. BMC Immunology. 10(1). 19–19. 43 indexed citations
11.
Ratliff, Kevin S., Aleksandr Petrov, George J. Eiermann, et al.. (2008). An Automated Electrophysiology Serum Shift Assay for K V Channels. Assay and Drug Development Technologies. 6(2). 243–253. 6 indexed citations
12.
Kaelin, David E., George J. Eiermann, Huaibing He, et al.. (2007). 4-Arylcyclohexylalanine analogs as potent, selective, and orally active inhibitors of dipeptidyl peptidase IV. Bioorganic & Medicinal Chemistry Letters. 17(21). 5806–5811. 17 indexed citations
13.
Liang, Gui‐Bai, Xiaoxia Qian, Dennis Feng, et al.. (2007). Optimization of 1,4-diazepan-2-one containing dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Bioorganic & Medicinal Chemistry Letters. 17(7). 1903–1907. 27 indexed citations
14.
Leiting, Barbara, KellyAnn D. Pryor, Frank Marsilio, et al.. (2007). Design, synthesis, and biological evaluation of triazolopiperazine-based β-amino amides as potent, orally active dipeptidyl peptidase IV (DPP-4) inhibitors. Bioorganic & Medicinal Chemistry Letters. 17(21). 5934–5939. 32 indexed citations
15.
Kim, Dooseop, Scott D. Edmondson, Anthony Mastracchio, et al.. (2007). Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: Close analogs of JANUVIA™ (sitagliptin phosphate). Bioorganic & Medicinal Chemistry Letters. 17(12). 3373–3377. 39 indexed citations
16.
Biftu, Tesfaye, Dennis Feng, Xiaoxia Qian, et al.. (2006). (3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorganic & Medicinal Chemistry Letters. 17(1). 49–52. 34 indexed citations
17.
Xu, Jinyou, Lan Wei, Robert J. Mathvink, et al.. (2006). Discovery of potent, selective, and orally bioavailable oxadiazole-based dipeptidyl peptidase IV inhibitors. Bioorganic & Medicinal Chemistry Letters. 16(20). 5373–5377. 27 indexed citations
18.
Xu, Jinyou, Lan Wei, Robert J. Mathvink, et al.. (2005). Discovery of potent, selective, and orally bioavailable pyridone-based dipeptidyl peptidase-4 inhibitors. Bioorganic & Medicinal Chemistry Letters. 16(5). 1346–1349. 14 indexed citations
19.
Parmee, Emma R., Jiafang He, Anthony Mastracchio, et al.. (2003). 4-Amino cyclohexylglycine analogues as potent dipeptidyl peptidase IV inhibitors. Bioorganic & Medicinal Chemistry Letters. 14(1). 43–46. 34 indexed citations
20.
Forrest, M J, George J. Eiermann, Roger Meurer, Lori A. Walakovits, & D. Euan MacIntyre. (1992). The role of CD 18 in IL‐8 induced dermal and synovial inflammation. British Journal of Pharmacology. 106(2). 287–294. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hisashi Shinkai Breakdown of academic impact, for papers by Jeffrey A. Robl Breakdown of academic impact, for papers by Nobuyuki Negoro Breakdown of academic impact, for papers by T. Saeki Breakdown of academic impact, for papers by Yū Momose Breakdown of academic impact, for papers by Franklin Liu Breakdown of academic impact, for papers by Robert J. Ife Breakdown of academic impact, for papers by Paige E. Mahaney Breakdown of academic impact, for papers by Ernst U. Frevert Breakdown of academic impact, for papers by Ralph Mosley
Rankless by CCL
2026